top of page

Free Biopharma Daily Stock Updates - 07/26/21

$XBI $124.22 -1.80%

 

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

 

Covid Updates

$TRVN -5.40% Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19. source


Pipeline Updates

$IONS -1.60% Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC source


$BCEL +5.0% Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101 source


$AGRX -3.5% Agile Therapeutics Reports Second Quarter 2021 Financial Results source


$CERC -2.50% Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients source


$BNTX +1.50% BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address Infectious Diseases on the African Continent. source


$CRTX -7.30% Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021. source


$PRTA -1.0% Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021. source


$INMB -23.0% INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data. source


$SAVA -2.80% Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam. source


$ELDN -4.4% Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation. source


$SESN -2.9% Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US. source


$ISEE -1.0% Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule. source


$ABEO +0.80% Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy. source


$QURE +3.4% uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress. source


$ATNX -2.40% Athenex Announces Additional Licensing Agreements for Tirbanibulin. source


$XENT +9.3% U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis. source


$MDWD -0.50% MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma. source


$ITRM -44.2% Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem. source


$DNLI -15.3% Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II). source


$TARS -4.2% Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021. source


Financial Updates

$PLXP -2.0% PLx Pharma Inc.’s VAZALORE to Launch in Over 2,400 Rite Aid Stores in August source


$SBBP -3.5% Strongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with the Proposed Acquisition by Xeris Pharmaceuticals, Inc. source

 

Posted by FS/JM

0 comments
bottom of page